ResourcesLearn from our biopharma experts, explore stimulating thought leadership and see some of our clients’ past successes.
The Prescient team has prepared a white paper discussing our view on the recent advances in the CAR-T landscape. Industry and academia appear to be making significant strides in simplifying manufacturing and administration processes, expanding clinical utility and enabling access for patients. By: Ben Doran, Stuart Crichton, Ben Druck and Vasiliki Patsioura Click below and complete the form to receive the white paper via email.Read More
By: Mackie Adoniadis Prescient is committed to respecting our clients’ privacy and personal data. Over the past few months, we have audited the personal data we hold and reviewed the processes we use. We are busy making changes to our systems and policies to incorporate the General Data Protection Regulation (GDPR) standards as they relate to our business.
Our global pharmaceutical client was developing a suite of biosimilars that it intended to commercialize in several Latin American countries. The client engaged Prescient to investigate regulatory, pricing, reimbursement and purchasing models to generate volume and revenue forecasts (through 2025) and quantify the market opportunity for the biosimilars in these countries.
By: Tanya Casimiro, PhDAs the first Phase III data in non-alcoholic steatohepatitis (NASH) begin to be released, the next 12 months will prove crucial to understanding which drivers will shape the NASH market. Key questions of interest to stakeholders will be answered, such as:
By: Ben DoranPersonalized healthcare: An overview There is significant interest in companion diagnostics (CDx) throughout the healthcare industry, but for this personalized medicine approach to continue to gain traction, numerous technical and commercial challenges need to be overcome. At Prescient Healthcare Group, our experts who are closely monitoring CDx developments across therapeutic areas hav[...]
By: Joanne Taylor, PhDApproximately 7,000 rare diseases affect more than 300 million people worldwide, or around 5-8% of the population, depending on the market. The number of patients diagnosed with individual rare diseases varies enormously: One disease may affect only a handful of patients while others affect hundreds of thousands. Eighty percent of rare diseases have an identified genetic origin and half af[...]
By: Ben DoranOn April 16, 2018, data from multiple pivotal trials in first-line (1L) non-small-cell lung cancer (NSCLC) were presented at the American Association for Cancer Research (AACR) Annual Meeting 2018. Clearly, the need to publish data in an expediated fashion is more important than ever for companies developing cancer immunotherapies. Below are Prescient Healthcare Group’s key takeaways from the d[...]
Our client, a global pharmaceutical company, was in the process of strengthening the vision for its future product portfolio. The marketing team needed to identify potential high-prescribing customers to develop a marketing campaign that would support its strategy for optimally co-positioning future therapies. There were several unknowns about the potential license for our client’s product, so Prescient was engaged to develop strong, focused positioning concepts that would resonat[...]
Our global pharmaceutical client’s mature product was two years away from patent expiry in its key regulated markets and faced imminent generic competition. The company engaged Prescient to understand the likely impact of changes in the competitive landscape, market dynamics and stakeholder behavior.
By: Ben DruckThe US healthcare system has been facing great uncertainty, with ongoing challenges to the sustainability of the Affordable Care Act and converging industry pressures on pharmaceutical drug pricing. At Prescient Healthcare Group, our healthcare experts are closely monitoring developments in managed care and health policy, and have observed three key trends influencing the US market access landsca[...]
Our client, a global pharmaceutical company, sought to decide whether to progress two internal assets into Phase III development based on the Phase II data. The client engaged Prescient to: 1) perform an in-depth assessment of the Phase II data and comparative analyses with in-line and pipeline competitor products; 2) evaluate the potential changes in the regulatory requirements; 3) analyze the impact of the potential entry of biosimilars and their ability to disrupt the marketplace[...]